查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1649494

抗凝血劑市場：預測（2025-2030 年）

Anticoagulants Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

抗凝血劑市場預計將從 2025 年的 411.71 億美元成長到 2030 年的 713.12 億美元，複合年成長率為 11.61%。

由於心血管疾病盛行率顯著上升以及靜脈血栓栓塞症和動脈血栓症病例數量的增加，預計抗凝血劑市場在整個預測期內將保持穩定成長。抗凝血劑是專門用於預防血栓的藥物，尤其適用於高風險族群。血栓會阻塞血管，導致大腦、肺和心臟等重要器官無法獲得足夠的血液流向。這種阻塞可能導致嚴重的併發症，包括因缺氧而導致的器官損傷。此外，心房顫動等情況會導致血栓形成，從而導致心臟衰竭、中風和其他心臟相關問題。全球肥胖人數的增加進一步加劇了血栓相關心臟病的流行。此外，由於免疫力較弱和其他健康因素，老年人罹患血栓的風險更高。全球肥胖率的上升和老年人口的增加是預計未來幾年推動抗凝血劑需求的主要因素。此外，這些藥物通常在心血管手術中使用以防止血栓，隨著全球此類手術數量的增加，市場成長預計也會增加。

抗凝血劑市場的關鍵促進因素

  • 心臟病發病率不斷上升：被診斷患有心臟病的患者數量不斷增加是抗凝血劑市場發展的主要驅動力。根據世界衛生組織（WHO）的數據，心血管疾病（CVD）後果嚴重，每年約有1,790萬人死於此類疾病，約佔全球死亡人數的31%。吸菸、營養不良和缺乏運動等因素會增加心臟病和中風的發生率。在美國，心臟病仍然是第一大死因，其中以冠心病最為常見。肥胖人口的不斷成長是心臟病發作的一個重要因素，隨著醫療保健提供者專注於識別風險因素和實施有效的治療方法，對抗凝劑的需求也隨之增加。
  • 心臟病發作後的治療：抗凝血劑對心臟病發作的患者特別有益，有助於降低後續事件的風險。例如，美國每年約有72.5萬人心臟病發作，其中約30％會復發。這一趨勢將對預測期內抗凝血劑市場的成長產生正面影響。

區域展望

  • 北美：全球抗凝血劑市場分為北美、南美、歐洲、中東和非洲以及亞太等地區。由於北美擁有先進的醫療保健基礎設施和對該領域的持續投資，預計將佔據該市場的大部分佔有率。心血管疾病發病率的上升和對創新治療的重視程度的提高進一步推動了該地區的成長。
  • 亞太地區：受中國和印度等國家廣泛的鐵路網路的推動，該地區預計也將顯著成長。政府旨在改善醫療保健服務的措施也將促進市場擴張。

總之，由於醫療保健投資的增加、需要抗凝血治療的外科手術的增加、心血管疾病發生率的上升以及人口老化，抗凝血藥物市場預計將成長。

為什麼要購買這份報告？

  • 深刻分析：獲得涵蓋主要和新興地區的深入市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中開闢新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問公司、中小企業和大型企業都有益且具有成本效益。

它有什麼用途？

產業與市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

  • 2022 年至 2030 年的實際資料和預測
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭定位、策略與市場佔有率分析
  • 各地區（包括細分市場和國家）的收益成長和預測分析
  • 公司概況（策略、產品、財務、主要發展等）

目錄

第 1 章 簡介

  • 市場概況
  • 市場定義
  • 研究範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 研究過程

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
  • 產業價值鏈分析

5. 抗凝血藥市場（依藥物類別分類）

  • 介紹
  • 維生素 K 拮抗劑（香豆素抗凝血劑）
  • 低分子量肝素 (LMWH)
  • 直介面服抗凝血劑 (DOAC)
  • 其他

第6章 抗凝血劑市場（依應用）

  • 介紹
  • 心房顫動
  • 心臟病發作
  • 深層靜脈栓塞症
  • 肺動脈栓塞
  • 其他

7. 抗凝血劑市場（按分銷管道）

  • 介紹
  • 醫院藥房
  • 零售藥局
  • 線上

8. 抗凝血劑市場（按地區）

  • 介紹
  • 北美洲
    • 按藥品類別
    • 按應用
    • 按分銷管道
    • 按國家
  • 南美洲
    • 按藥品類別
    • 按應用
    • 按分銷管道
    • 按國家
  • 歐洲
    • 按藥品類別
    • 按應用
    • 按分銷管道
    • 按國家
  • 中東和非洲
    • 按藥品類別
    • 按應用
    • 按分銷管道
    • 按國家
  • 亞太地區
    • 按藥品類別
    • 按應用
    • 按分銷管道
    • 按國家

第9章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭儀錶板

第10章 公司簡介

  • Aspen Holdings
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol Myers Squibb Company
  • Alexion Pharmaceuticals, Inc.
  • Daiichi Sankyo, Inc.
  • Anthos Therapeutics
  • AcelRx Pharmaceuticals, Inc.
簡介目錄
Product Code: KSI061613518

The anticoagulants market is projected to grow at a CAGR of 11.61%, from US$41.171 billion in 2025 to US$71.312 billion in 2030.

The anticoagulant market is expected to experience steady growth throughout the forecast period, driven by a significant rise in the prevalence of cardiovascular diseases, as well as an increase in cases of venous thromboembolism and arterial thrombosis. Anticoagulants are medications designed to prevent blood clots, particularly for individuals at high risk. These medications are crucial for those susceptible to clots, helping to reduce the likelihood of severe heart conditions such as heart attacks and strokes.Blood clots can obstruct blood vessels, preventing essential organs-including the brain, lungs, and heart-from receiving adequate blood flow. This obstruction can lead to serious complications, including organ damage due to lack of oxygen. Conditions like atrial fibrillation can also result in blood clot formation, leading to heart failure, strokes, and other heart-related issues. The global rise in obesity is further contributing to the prevalence of heart diseases associated with blood clots.Additionally, older adults are at a higher risk for clotting due to weakened immune systems and other health factors. The increasing rates of obesity and the growing global geriatric population are key drivers anticipated to boost demand for anticoagulant medications in the coming years. Furthermore, these drugs are commonly administered during heart surgeries to prevent clot formation, which is expected to further enhance market growth as the number of such procedures rises globally.

Key Drivers of the Anticoagulants Market

  • Increasing Prevalence of Heart Diseases: The rising number of individuals diagnosed with heart disease is a primary driver for the anticoagulant market. Cardiovascular diseases (CVDs) have severe consequences; according to the World Health Organization (WHO), approximately 17.9 million people die from these diseases annually, accounting for about 31% of all global deaths. Factors such as smoking, poor nutrition, and lack of physical activity have contributed to higher rates of heart attacks and strokes. In the United States, heart disease remains the leading cause of death, with coronary heart disease being the most common type. The growing obese population is a significant contributor to heart attacks, driving demand for anticoagulants as healthcare providers focus on identifying risk factors and implementing effective treatments.
  • Post-Heart Attack Treatment: Anticoagulants are particularly beneficial for patients who have experienced a heart attack, as they help reduce the risk of subsequent events. For instance, approximately 725,000 people in the U.S. suffer a heart attack each year, with around 30% being repeat cases. This trend positively impacts the growth of the anticoagulant market during the forecast period.

Geographical Outlook

  • North America: The global anticoagulant market is segmented into regions including North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America is projected to hold a significant share of this market due to its advanced healthcare infrastructure and ongoing investments in this sector. The region's growth is further supported by increasing incidences of cardiovascular diseases and a strong emphasis on innovative treatments.
  • Asia Pacific: This region is also expected to witness substantial growth driven by extensive rail networks in countries like China and India. Government initiatives aimed at improving healthcare access will also contribute to market expansion.

In summary, the anticoagulant market is poised for growth driven by rising rates of cardiovascular diseases and an aging population alongside increased healthcare investments and surgical procedures requiring anticoagulation therapy.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Market Segmentation:

The anticoagulants market is segmented and analyzed as below:

By Drug Class

  • Vitamin K antagonists (coumarin anticoagulants)
  • Low molecular weight heparins (LMWH)
  • Direct Oral Anticoagulants (DOACs)
  • Others

By Application

  • Atrial Fibrillation
  • Heart Attacks
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ANTICOAGULANTS MARKET BY DRUG CLASS

  • 5.1. Introduction
  • 5.2. Vitamin K antagonists (coumarin anticoagulants)
  • 5.3. Low molecular weight heparins (LMWH)
  • 5.4. Direct Oral Anticoagulants (DOACs)
  • 5.5. Others

6. ANTICOAGULANTS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Atrial Fibrillation
  • 6.3. Heart Attacks
  • 6.4. Deep Vein Thrombosis
  • 6.5. Pulmonary Embolism
  • 6.6. Others

7. ANTICOAGULANTS MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Retail Pharmacy
  • 7.4. Online

8. ANTICOAGULANTS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Drug Class
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Drug Class
    • 8.3.2. By Application
    • 8.3.3. By Distribution Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Drug Class
    • 8.4.2. By Application
    • 8.4.3. By Distribution Channel
    • 8.4.4. By Country
      • 8.4.4.1. UK
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Drug Class
    • 8.5.2. By Application
    • 8.5.3. By Distribution Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. Israel
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Drug Class
    • 8.6.2. By Application
    • 8.6.3. By Distribution Channel
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. South Korea
      • 8.6.4.4. India
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Taiwan
      • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Aspen Holdings
  • 10.2. Bayer AG
  • 10.3. Boehringer Ingelheim International GmbH
  • 10.4. Pfizer Inc.
  • 10.5. Johnson & Johnson Services, Inc.
  • 10.6. Bristol Myers Squibb Company
  • 10.7. Alexion Pharmaceuticals, Inc.
  • 10.8. Daiichi Sankyo, Inc.
  • 10.9. Anthos Therapeutics
  • 10.10. AcelRx Pharmaceuticals, Inc.